



## **Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day**

February 1, 2016

WASHINGTON, Feb. 1, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel therapies addressing high unmet medical needs, today announced that members of its management team will participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day on Tuesday, February 2, 2016 in New York City.

For more on Vanda Pharmaceuticals Inc., please visit [www.vandapharma.com](http://www.vandapharma.com).

### **Investor Contact:**

Jim Kelly  
Senior Vice President and Chief Financial Officer  
Vanda Pharmaceuticals Inc.  
(202) 734-3428  
[jim.kelly@vandapharma.com](mailto:jim.kelly@vandapharma.com)

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-participate-in-the-canaccord-genuity-rare-disease-biopharma-one-on-one-day-300213055.html>

SOURCE Vanda Pharmaceuticals Inc.